The effect of Portulaca oleracea syrup on mild to moderate chronic hand dermatitis

Phase 3

Conditions: mild to moderate chronic dermatitis.
Dermatitis, unspecified
L30.9

Registration Number: IRCT20200707048040N1

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 70

Inclusion Criteria

Patients with chronic unilateral or bilateral hand dermatitis, including occupational dermatitis, allergic dermatitis or irritative dermatitis
Age range 18 to 70 years
Willingness and satisfaction to participate in the study
Referred to traditional medicine center

Exclusion Criteria

Breastfeeding
Pregnancy
Patients with severe dermatitis
Patients with underlying diseases such as cardiovascular failure, diabetes, immune deficiency, autoimmune diseases, spinal cord diseases
Patients taking medication for their other illnesses
Patients who develop another acute illness during treatment
Patients who have an infection at the site of their dermatitis
Patients who are allergic to Portulaca oleracea

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Erythema. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: HECSI Scale.;Edema. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: HECSI Scale.;Fissure. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: HECSI Scale.;Scaling. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: HECSI Scale.;Itching. Timepoint: Week zero, the end of the second, fourth and eighth weeks. Method of measurement: VAS Scale.;Dryness. Timepoint: Week zero, the end of the second, fourth and eighth weeks. Method of measurement: VAS Scale.;Skin thickness. Timepoint: Week zero, the end of the second, fourth and eighth weeks. Method of measurement: VAS Scale.;Drug side effects. Timepoint: Week zero, the end of the second, fourth and eighth weeks. Method of measurement: Question from the patient.

Secondary Outcome Measures

Name	Time	Method
Dermatology life quality index. Timepoint: Week zero, the end of the fourth and eighth weeks. Method of measurement: DLQI questionnair.;Patients' overall satisfaction with treatment. Timepoint: End of the fourth week. Method of measurement: Likert Scale.;Recurrence of symptoms after treatment. Timepoint: the end of the eighth week. Method of measurement: Question from the patient.